News >

Immunotherapy Remains Focal Point in TNBC

Caroline Seymour
Published: Friday, Jul 27, 2018

Sylvia Adams, MD

Sylvia Adams, MD
Standard chemotherapy is insufficient in the treatment of patients with triple-negative breast cancer (TNBC), but combining chemotherapy with immunotherapy may be key to unleashing the immunogenicity identified in TNBC, explained Sylvia Adams, MD.

“Harnessing that [immunogenicity] and using therapies to augment that immune response can make a difference in patient outcomes,” said Adams, associate professor, Department of Medicine, director, Clinical Research, Breast Cancer Disease Management Group, NYU Langone’s Perlmutter Cancer Center.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication